CNS Pharmaceuticals reports Q3 results

Nov. 15, 2022 6:41 AM ETCNS Pharmaceuticals, Inc. (CNSP)By: Deepa Sarvaiya, SA News Editor
  • CNS Pharmaceuticals press release (NASDAQ:CNSP): Q3 Net loss of $3.4M
  • As of September 30, 2022, the Company had cash of approximately $7.0 million and working capital of approximately $7.5 million. The Company's current expectation is that the cash on hand and the proceeds from the offering during January is sufficient to fund our operations into the first quarter of 2023. 

  • Shares -2.42% PM.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.